EXPLORE MET PREVALENCE IN NSCLC
*Estimated prevalence in non-squamous NSCLC. Imagery is for illustrative purposes only and does not
proportionally represent biomarker prevalence as shown.
MET Biomarker Prevalence
Among MET aberrations, c-Met protein overexpression occurs in ~25%-37% of patients with NSCLC.*1,2 MET amplification occurs in ~2%-5% and METex14 skipping in ~2%-4% of these patients.2
*Estimated prevalence in non-squamous NSCLC.
Biomarker prevalence estimates are based on multiple sources. Prevalence data can vary among studies and data sets because of detection methodology used and patient sample sizes and/or demographic characteristics. Some patients may have more than one MET aberration.
Biomarkers included are select MET aberrations that are both emerging and established biomarkers in NSCLC. This is not an exhaustive list of all NSCLC biomarkers and selected MET aberrations may overlap with other NSCLC biomarkers.
Prevalence of Other Biomarkers in NSCLC
In addition to MET aberrations, the prevalence of other biomarkers in NSCLC varies. Biomarkers tested for in NSCLC include PD-L1, EGFR, ALK, BRAF, ROS-1, NTRK, as well as others. There may be overlap among biomarkers in NSCLC.13,14
c-Met protein overexpression and MET gene amplification are emerging biomarkers in clinical research as potential therapeutic targets.
There are no FDA-approved tests for c-Met protein overexpression or MET gene amplification.
Biomarkers included are select MET aberrations that are both emerging and established biomarkers in NSCLC. This is not an exhaustive list of all NSCLC biomarkers and selected MET aberrations may overlap with other NSCLC biomarkers.
MET aberration prevalence estimates and prognosis statements are based on multiple sources. Survival and prevalence data can vary among studies and data sets because of detection methodology used, patient sample sizes, and/or demographic characteristics. Some patients may have more than one MET aberration.